MiNK Therapeutics develops iNKT cell therapy candidates for cancers and graft versus host disease, still in clinical trials. INKT reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 21 | B. Riley Securities | Reiterated | Buy |
Seasonality
How INKT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in INKT in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INKT is in one of them and how their past INKT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered INKT in an article yet. Here's the latest on the wider market.
About MiNK Therapeutics
MiNK Therapeutics is a biotechnology company based in New York that develops cell therapies built on its iNKT cell platform. Its product candidates are still being tested in clinical trials and have not been approved for sale. The treatments are being studied for conditions such as graft versus host disease, solid tumors and multiple myeloma, and the company's intended customers are patients and the physicians who treat them. It competes with other cell therapy developers and with existing and newer treatments.
- Headquarters
- New York, NY